Vanda Pharmaceuticals Inc. (0LKB)
LSE 
Summary
0LKB Chart
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more substantial reductions anticipated in 2027.
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.
Vanda Pharmaceuticals Inc. (0LKB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vanda Pharmaceuticals Inc. ever had a stock split?
Vanda Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mihael H. Polymeropoulos CEO | LSE Exchange | 921659108 CUSIP |
| US Country | 533 Employees | - Last Dividend | - Last Split | 12 Apr 2006 IPO Date |
Overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for addressing high unmet medical needs on a global scale. With a focus on conditions that affect sleep-wake disorders, schizophrenia, and a variety of other medical conditions, Vanda Pharmaceuticals seeks to improve the quality of life for patients worldwide. Since its incorporation in 2002, and headquartered in Washington, D.C., the company has made significant strides in bringing novel treatments to the market and continues to expand its robust pipeline of promising therapeutic candidates.
Products and Services
- HETLIOZ (tasimelteon) – Marketed for the treatment of non-24-hour sleep-wake disorders. The pipeline for HETLIOZ includes potential applications for:
- Jet lag disorder
- Insomnia
- Delayed sleep phase disorder
- Sleep disturbances in autism spectrum disorder
- Pediatric Non-24
- Fanapt (iloperidone) oral tablets – Marketed for the treatment of schizophrenia, with ongoing development for:
- Bipolar I disorder
- Parkinson's disease psychosis
- A long-acting injectable (LAI) formulation for schizophrenia
- Tradipitant (VLY-686) – A small molecule neurokinin-1 receptor (NK-1R) antagonist in development for:
- Gastroparesis
- Motion sickness
- Atopic dermatitis
- COVID-19 pneumonia
- VTR-297 – A small molecule histone deacetylase inhibitor being studied for:
- Hematologic malignancies
- Various oncology indications
- VQW-765 – A small molecule nicotinic acetylcholine receptor partial agonist under investigation for:
- Performance anxiety
- Psychiatric disorders
- VHX-896 – An active metabolite of iloperidone in development.
- Antisense Oligonucleotide Molecules – Under investigation for various indications.
- Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators and Inhibitors, including:
- VSJ-110 for the treatment of dry eye and ocular inflammation
- VPO-227 for treating secretory diarrhea disorders such as cholera
